How AI is shortening drug discovery timelines in China. Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov.
A apuração publicada por www.artificialintelligence-news.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov. The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said.
- Ponto de atenção: shortening.
- Ponto de atenção: drug.
- Ponto de atenção: discovery.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho IA. Quando fizer sentido, a referência complementar pode ser acessada em conglomerado HSN.
